• Viral infections

Synagis Generic Name & Formulations

General Description

Palivizumab 50mg/vial, 100mg/vial; liq soln for IM inj; preservative-free.

Pharmacological Class

Antiviral monoclonal antibody (IgG1K).

How Supplied

Single-use vials (soln)—1


Synagis Indications


Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (≤35 weeks gestational age) and who are ≤6 months of age at the beginning of RSV season; with bronchopulmonary dysplasia that required medical treatment within the previous 6 months and who are ≤24 months of age at the beginning of RSV season; with hemodynamically significant congenital heart disease and who are ≤24 months of age at the beginning of RSV season.

Limitations of Use

Not established for treatment of RSV disease.

Synagis Dosage and Administration


Not applicable.


Give by IM injection into anterolateral thigh. 15mg/kg once per month before and during RSV season. Cardiopulmonary bypass: see full labeling. Divide doses >1mL into 2 inj sites.

Synagis Contraindications

Not Applicable

Synagis Boxed Warnings

Not Applicable

Synagis Warnings/Precautions


Have epinephrine (1:1000) inj available. Thrombocytopenia. Coagulation disorders. May interfere with RSV diagnostic tests (eg, antigen detection-based assays), viral culture assays. Pregnancy, nursing mothers: not indicated.

Synagis Pharmacokinetics

See Literature

Synagis Interactions

Synagis Adverse Reactions

Adverse Reactions

Anaphylaxis, hypersensitivity reactions, fever, rash.

Synagis Clinical Trials

See Literature

Synagis Note

Not Applicable

Synagis Patient Counseling

See Literature